Applied Protein Sciences and Biomodels Collaborate to Boost Supportive Cancer Care

MOUNTAIN VIEW, Calif.–(Business Wire)–
Applied Protein Sciences, a biotechnology start-up focused on preventing mucositis, announced today that it has entered into a strategic alliance with Biomodels. This alliance allows speedier product development and helps APS expand its pipeline to develop proprietary drugs for mucositis, proctitis and IBD. APS expects to launch its clinical program later this year.

“We are very excited about partnering with Biomodels,” said Aman Johar, CEO of APS.”This relationship allows us flexibility to customize our pre-clinical studies, maintain our clinical end-points and effectively utilize capital resources. A full-scale collaboration extends our research platform and provides access to leading scientists and researchers. Biomodels` proven models reliably predict clinical success in an extremely complex field of mucositis. APS products can be the standard of care for preventing mucositis – saving over $2 billion annually in hospitalization costs.”

“Together Biomodels and APS will finalize oral mucositis studies and also rapidly test a number of mechanistically-related therapeutic areas using appropriate validated models,” said Edward Fey, Managing Partner of Biomodels. “This alliance represents a new business model for the outsourcing of pre-clinical services and is designed to fulfill the specific needs of early stage pharmaceutical companies,” Fey adds.

Mucositis remains an unmet medical need and APS products may become the “standard of care”for solid tumor patients undergoing cancer treatment. Mucositis affects over 400,000 patients annually. In a recent survey, 66% of mucositis patients said that physicians need to
be educated more about its treatments. There are currently no approved medications for preventing
mucositis. This collaboration boosts APS efforts to build a technology platform that can be scaled to encompass all aspects of supportive oncology care.

About Applied Protein Sciences

APS is developing proprietary proteins that help with the growth of the mucosal tissue, thereby preventing the onset of mucositis. With APS` products, patients can remain on chemotherapy or radiation for longer, significantly increasing their survival. In addition to
mucositis, APS drug platform includes candidates for proctitis and IBD – significant unmet medical needs in supportive oncology care. APS aims to secure orphan drug status and has a broad
portfolio of issued US and worldwide patents rights. APS recently released a mechanism of action for its drug candidates. APS is privately owned and investors include Innovation Management Sciences.

About Biomodels

Biomodels is a preclinical CRO helping biotechnology companies enter clinical trials phase of the drug development process. Biomodels specializes in screening studies to evaluate efficacy and define mechanism of action to expedite the process. Over the years Biomodels core competencies in oncology and cancer supportive care include a range of inflammatory and mucosal diseases. The net effects are preclinical data that are meaningfully translatable to the clinic and added confidence in the design of clinical studies, all of which conveys substantial cost savings.